Efficacy of voriconazole in Japanese quail (Coturnix japonica) experimentally infected with Aspergillus fumigatus

Medical Mycology

Volumn 48, Issue 2, 2010, Pages 234-244

  Tell, Lisa A ^a   Clemons, Karl V ^b,c,d   Kline, Yvonne ^a   Woods, Leslie ^e   Kass, Philip H ^e   Martinez, Marife ^b   Stevens, David A ^b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antifungal; Aspergillosis; Avian; Fungal infection; Voriconazole

Indexed keywords

DILUENT; EOSIN; HEMATOXYLIN; METHENAMINE; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS FUMIGATUS; BIRD DISEASE; COLONY FORMING UNIT; CONTROLLED STUDY; COTURNIX; COTURNIX JAPONICA; DISEASE MODEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; FUNGAL COLONIZATION; HISTOPATHOLOGY; IC 50; IMMUNOHISTOCHEMISTRY; LUNG ASPERGILLOSIS; LUNG LESION; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NECROSIS; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; TIME TO MAXIMUM PLASMA CONCENTRATION;

ASPERGILLUS FUMIGATUS; AVES; COTURNIX JAPONICA; FUNGI; PHASIANIDAE;

EID: 76649134835     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780903008821     Document Type: Article

References (48)

1. Tell LA. Aspergillosis in mammals and birds: impact on veterinary medicine. Med Mycol 2005; 43 ( Suppl. 1 ): S71 - 73 .
2. Orosz SE . Antifungal drug therapy in avian species . Vet Clin North Am Exot Anim Pract 2003 ; 6 : 337-350 .
3. Orosz SE, Frazier DL. Antifungal agents: a review of their pharmacology and therapeutic indications. J Avian Med Surg 1995; 9: 8-18 .
4. Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310-344 .
5. Denning DW, Lee JY, Hostetler JS, et al. NIAID mycoses study group multicenter trial of oral itraconazoletherapy for invasive aspergillosis. Am J Med 1994; 97: 135-144 .
6. Walsh TJ, Anaissie EJ, Denning DW, et al. Guidelines for thetreatment of aspergillosis (Infectious Diseases Society of America practice guidelines). Clin Infect Dis 2008; 46: 327-360 .
7. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazoletreatment. Blood 2005; 106: 2641-2645 .
8. Mouas H, Lutsar I, Dupont B, et al. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 2005; 40: 1141-1147 .
9. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-637 .
10. Kofla G, Ruhnke M. Voriconazole: review of a broad spectrum triazole antifungal agent. Expert Opin Pharmacother 2005; 6: 1215-1229 .
11. Capitano B, Potoski BA, Husain S, et al. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob Agents Chemother 2006; 50: 1878-1880 .
12. Krishnan S, Manavathu EK, Chandrasekar PH. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus . J Antimicrob Chemother 2005; 55: 914-920 .
13. Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative effi cacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005; 49: 4867-4875 .
14. Clemons KV, Parmar R, Martinez M, Stevens DA. Efficacy of Abelcet al.one, or in combination therapy, against experimental central nervous system aspergillosis. J Antimicrob Chemother 2006; 58: 466-469 .
15. Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Med Mycol 2006; 44: 69-73 .
16. Kirkpatrick WR, McAtee RK, Fothergill AW, Rinaldi MG, Patterson TF. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 2865-2868 .
17. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 3165-3169 . (Pubitemid 37229574)
18. Roffey SJ, Cole S, Comby P, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 2003; 31: 731-741 .
19. Colitz CM, Latimer FG, Cheng H, et al.. Pharmacokinetics of voriconazole following intravenous and oral administration and body fl uid concentrations of voriconazole following repeated oral administration in horses. Am J Vet Res 2007; 68: 1115-1121 .
20. Davis JL, Salmon JH, Papich MG. Pharmacokinetics of voriconazole after oral and intravenous administration to horses. Am J Vet Res 2006; 67: 1070-1075 .
21. Clode AB, Davis JL, Salmon J, Michau TM, Gilger BC. Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses. Am J Vet Res 2006; 67: 296-301 .
22. Leveque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006; 27: 274-284 .
23. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45: 649-663 .
24. Flammer K, Nettifee Osborne JA, Webb DJ, et al. Pharmacokinetics of voriconazole after oral administration of single and multiple doses in African grey parrots ( Psittacus erithacus timneh ). Am J Vet Res 2008; 69: 114-121 .
25. Beernaert LA, Baert K, Marin P, et al.. Designing voriconazoletreatment for racing pigeons: balancing between hepatic enzyme auto induction and toxicity. Med Mycol 2008; 46: 1-10 .
26. Burhenne J, Haefeli WE, Hess M, Scope A. Pharmacokinetics, tissue concentrations, and safety of the antifungal agent voriconazole in chickens. J Avian Med Surg 2008; 22: 199-207 .
27. Schmidt V, Demiraj F, Di Somma A, et al. Plasma concentrations of voriconazole in falcons. Vet Rec 2007; 161: 265-268 .
28. Ette EI, Williams PJ. Population pharmacokinetics II: estimation methods. Ann Pharmacother 2004; 38: 1907-1915 .
29. Stevens DA, Aristizabal BH. In vitro antifungal activity of novel azole derivatives with a morpholine ring, UR-9746 and UR-9751, and comparison with fluconazole. Diagn Microbiol Infect Dis 1997; 29: 103-106 .
30. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidiumforming filamentousfungi . Proposed standard M38-A . National Committee for Clinical Laboratory Standards, Wayne, Pa . 1998 .
31. Hanson LH, Clemons KV, Denning DW, Stevens DA. Efficacy of oral saperconazole in systemic murine aspergillosis. J Med Vet Mycol 1995; 33: 311-317 .
32. Denning DW, Clemons KV, Stevens DA. Quantitative preservation of viability of Aspergillus fumigatus . J Med Vet Mycol 1992; 30: 485-488 .
33. Clemons KV, Stevens DA. Conventional or molecular measurement of Aspergillus load. Med Mycol 2008; 47 ( Suppl. 1 ): S132-S137 .
34. Singh G, Imai J, Clemons KV, Stevens DA. Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods. Antimicrob Agents Chemother. 2005; 49: 1369-1376 .
35. Rex JH, Hanson LH, Amantea MA, Stevens DA, Bennett JE. Standardization of a fluconazole bioassay and correlation of results with those obtained by high-pressure liquid chromatography. Antimicrob Agents Chemother 1991; 35: 846-850 .
36. Hoeprich PD, Finn PD. Obfuscation of the activity of antifungal antimicrobics by culture media. J Infect Dis 1972; 126: 353-361 .
37. Silvanose CD, Bailey TA, Di Somma A. Susceptibility of fungi isolated from the respiratory tract of falcons to amphotericin B, itraconazole and voriconazole. Vet Rec 2006; 159: 282-284 .
38. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415 . (Pubitemid 34851833)
39. Shih W. Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med 2002; 3: 4 .
40. Lachin JM. Worst-rank score analysis with informatively missing observations in clinical trials. Control Clin Trials 1999; 20: 408-422 .
41. Purkins L, Wood N, Ghahramani P, et al.. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-2553 .
42. Patterson B , Coates P . UK-109,496, a novel, wide spectrum triazole derivative for thetreatment of fungal infections: disposition in man . Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995 ; Abstract F76 .
43. Sugar AM, Liu XP. Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med Mycol 2000; 38: 209-212 .
44. Graybill JR, Najvar LK, Gonzalez GM, Hernandez S, Bocanegra R. Improving the mouse model for studying the Efficacy of voriconazole. J Antimicrob Chemother 2003; 51: 1373-1376 .
45. Di Somma A, Bailey T, Silvanose CD, Garcia-Martinez C. The use of voriconazole for thetreatment of aspergillosis in falcons ( Falco Species). J Avian Med Surg 2007; 21: 307-316 .
46. Serena C, Pastor FJ, Marine M, Rodriguez MM, Guarro J. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection. J Antimicrob Chemother 2007; 60: 162 - 165 .
47. Carrasco L, Bautista MJ, de las Mulas JM, Jensen HE. Application of enzyme- immunohistochemistry for the diagnosis of aspergillosis, candidiasis, and zygomycosis in three lovebirds. Avian Dis 1993; 37: 923-927 .
48. Jensen HE, Christensen JP, Bisgaard M, Nielsen OL. Immunohistochemistry for the diagnosis of aspergillosis in turkey poults. Avian Path 1997; 26: 5-18 .